United Capital Financial Advisors LLC bought a new stake in Corteva, Inc. (NYSE:CTVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 43,210 shares of the company's stock, valued at approximately $3,659,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Arbejdsmarkedets Tillaegspension bought a new position in shares of Corteva during the 4th quarter worth about $23,679,000. Jupiter Topco LLC acquired a new position in Corteva during the 2nd quarter worth approximately $544,246,000. Bank of New York Mellon Corp bought a new position in Corteva in the second quarter worth approximately $392,447,000. Leonteq Securities AG acquired a new stake in Corteva in the fourth quarter valued at approximately $2,350,000. Finally, Brandes Investment Partners LP grew its stake in Corteva by 1.1% in the fourth quarter. Brandes Investment Partners LP now owns 2,312,515 shares of the company's stock valued at $155,009,000 after acquiring an additional 24,985 shares during the period. 81.54% of the stock is currently owned by hedge funds and other institutional investors.
Corteva Trading Up 1.9%
Shares of Corteva stock opened at $84.00 on Friday. The stock has a fifty day simple moving average of $82.69 and a 200 day simple moving average of $80.54. Corteva, Inc. has a 12-month low of $60.53 and a 12-month high of $90.97. The company has a market capitalization of $56.04 billion, a P/E ratio of 55.63, a price-to-earnings-growth ratio of 2.53 and a beta of 0.57. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.07.
Corteva (NYSE:CTVA - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.30 EPS for the quarter, beating analysts' consensus estimates of $2.24 by $0.06. The business had revenue of $6.38 billion during the quarter, compared to analyst estimates of $6.60 billion. Corteva had a return on equity of 10.18% and a net margin of 5.66%.Corteva's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.20 EPS. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. On average, sell-side analysts anticipate that Corteva, Inc. will post 3.72 earnings per share for the current fiscal year.
Corteva Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 1st. Corteva's dividend payout ratio (DPR) is presently 47.68%.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on CTVA shares. Barclays upped their target price on Corteva from $84.00 to $91.00 and gave the stock an "overweight" rating in a research report on Thursday, June 11th. Royal Bank Of Canada restated an "overweight" rating on shares of Corteva in a research note on Friday. Weiss Ratings lowered shares of Corteva from a "hold (c+)" rating to a "hold (c)" rating in a research note on Monday, August 3rd. Mizuho lifted their price objective on shares of Corteva from $96.00 to $97.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. Finally, CICC Research boosted their target price on shares of Corteva from $80.00 to $93.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 13th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $91.50.
View Our Latest Stock Report on Corteva
Corteva Company Profile
(
Free Report)
Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
Recommended Stories
Want to see what other hedge funds are holding CTVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corteva, Inc. (NYSE:CTVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Corteva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corteva wasn't on the list.
While Corteva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.